Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$11.94 - $16.09 $656 - $884
-55 Closed
0 $0
Q2 2021

Aug 12, 2021

SELL
$14.36 - $20.93 $861 - $1,255
-60 Reduced 52.17%
55 $1,000
Q4 2020

Jan 28, 2021

BUY
$15.87 - $31.64 $1,825 - $3,638
115 New
115 $3,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $82.8M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Fieldpoint Private Securities, LLC Portfolio

Follow Fieldpoint Private Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fieldpoint Private Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fieldpoint Private Securities, LLC with notifications on news.